These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 28095868)

  • 41. Increased levels of active c-Src distinguish invasive from in situ lobular lesions.
    Zou D; Yoon HS; Anjomshoaa A; Perez D; Fukuzawa R; Guilford P; Humar B
    Breast Cancer Res; 2009; 11(4):R45. PubMed ID: 19583841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast.
    Mastracci TL; Shadeo A; Colby SM; Tuck AB; O'Malley FP; Bull SB; Lam WL; Andrulis IL
    Genes Chromosomes Cancer; 2006 Nov; 45(11):1007-17. PubMed ID: 16897748
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma?
    Bagaria SP; Shamonki J; Kinnaird M; Ray PS; Giuliano AE
    Ann Surg Oncol; 2011 Jul; 18(7):1845-51. PubMed ID: 21287281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-invasive lobular neoplasia of the breast: Morphologic features, clinical presentation, and management dilemmas.
    Calle C; Kuba MG; Brogi E
    Breast J; 2020 Jun; 26(6):1148-1155. PubMed ID: 32500575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast.
    Green AR; Krivinskas S; Young P; Rakha EA; Paish EC; Powe DG; Ellis IO
    Breast Cancer Res Treat; 2009 Jan; 113(1):59-66. PubMed ID: 18213475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
    Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
    Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
    Hernandez L; Wilkerson PM; Lambros MB; Campion-Flora A; Rodrigues DN; Gauthier A; Cabral C; Pawar V; Mackay A; A'Hern R; Marchiò C; Palacios J; Natrajan R; Weigelt B; Reis-Filho JS
    J Pathol; 2012 May; 227(1):42-52. PubMed ID: 22252965
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomarker profile and genetic abnormalities in lobular carcinoma in situ.
    Mohsin SK; O'Connell P; Allred DC; Libby AL
    Breast Cancer Res Treat; 2005 Apr; 90(3):249-56. PubMed ID: 15830138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current Concepts in Diagnosis, Molecular Features, and Management of Lobular Carcinoma In Situ of the Breast With a Discussion of Morphologic Variants.
    Ginter PS; D'Alfonso TM
    Arch Pathol Lab Med; 2017 Dec; 141(12):1668-1678. PubMed ID: 28574280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia.
    Lu YJ; Osin P; Lakhani SR; Di Palma S; Gusterson BA; Shipley JM
    Cancer Res; 1998 Oct; 58(20):4721-7. PubMed ID: 9788628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.
    Cao L; Basudan A; Sikora MJ; Bahreini A; Tasdemir N; Levine KM; Jankowitz RC; McAuliffe PF; Dabbs D; Haupt S; Haupt Y; Lucas PC; Lee AV; Oesterreich S; Atkinson JM
    Cancer Lett; 2019 Oct; 461():21-30. PubMed ID: 31229512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
    Deniziaut G; Tille JC; Bidard FC; Vacher S; Schnitzler A; Chemlali W; Trémoulet L; Fuhrmann L; Cottu P; Rouzier R; Bièche I; Vincent-Salomon A
    Oncotarget; 2016 Nov; 7(45):73337-73346. PubMed ID: 27602491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors.
    Norton N; Advani PP; Serie DJ; Geiger XJ; Necela BM; Axenfeld BC; Kachergus JM; Feathers RW; Carr JM; Crook JE; Moreno-Aspitia A; Anastasiadis PZ; Perez EA; Thompson EA
    PLoS One; 2016; 11(4):e0153411. PubMed ID: 27078887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clonal profiling of mixed lobular and ductal carcinoma revealed by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
    Tajiri R; Inokuchi M; Sawada-Kitamura S; Kawashima H; Nakamura R; Oyama T; Dobashi Y; Ooi A
    Pathol Int; 2014 May; 64(5):231-6. PubMed ID: 24888777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma.
    Djerroudi L; Bendali A; Fuhrmann L; Benoist C; Pierron G; Masliah-Planchon J; Kieffer Y; Carton M; Tille JC; Cyrta J; Ramtohul T; Bonneau C; Caly M; Renault V; Bidard FC; Mechta-Grigoriou F; Vincent-Salomon A
    Mod Pathol; 2024 Oct; 37(10):100570. PubMed ID: 39025406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
    Mercapide J; Zhang SY; Fan X; Furió-Bacete V; Schneider J; López de la Osa I; Patchefsky AS; Klein-Szanto AJ; Castresana JS
    Mol Carcinog; 2002 Sep; 35(1):6-12. PubMed ID: 12203362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oncogenic PIK3CA mutations in lobular breast cancer progression.
    Christgen M; Noskowicz M; Schipper E; Christgen H; Heil C; Krech T; Länger F; Kreipe H; Lehmann U
    Genes Chromosomes Cancer; 2013 Jan; 52(1):69-80. PubMed ID: 22997091
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histopathologcial and clonal study of combined lobular and ductal carcinoma of the breast.
    Tazaki E; Shishido-Hara Y; Mizutani N; Nomura S; Isaka H; Ito H; Imi K; Imoto S; Kamma H
    Pathol Int; 2013 Jun; 63(6):297-304. PubMed ID: 23782331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.
    Bergeron A; MacGrogan G; Bertaut A; Ladoire S; Arveux P; Desmoulins I; Bonnefoi H; Loustalot C; Auriol S; Beltjens F; Degrolard-Courcet E; Charon-Barra C; Richard C; Boidot R; Arnould L
    Mod Pathol; 2021 Jul; 34(7):1282-1296. PubMed ID: 33753865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.